(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 5.04% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.
Abbvie's revenue in 2024 is $54,403,000,000.On average, 9 Wall Street analysts forecast ABBV's revenue for 2024 to be $97,639,182,475,570, with the lowest ABBV revenue forecast at $97,055,624,979,322, and the highest ABBV revenue forecast at $98,606,858,595,013. On average, 9 Wall Street analysts forecast ABBV's revenue for 2025 to be $103,687,124,229,130, with the lowest ABBV revenue forecast at $100,970,553,849,799, and the highest ABBV revenue forecast at $106,702,560,666,925.
In 2026, ABBV is forecast to generate $111,642,031,896,996 in revenue, with the lowest revenue forecast at $106,607,203,806,751 and the highest revenue forecast at $116,033,406,021,729.